Telomir Prescribed drugs Lead Drug Candidate Inhibits Tumor Development In Aggressive Prostate Most cancers Cells, Animal Examine Reveals – Telomir Prescribed drugs (NASDAQ:TELO)

On Wednesday, Telomir Prescribed drugs, Inc. TELO revealed preclinical findings demonstrating that Telomir-1 reduces tumor dimension by roughly 50% in a prostate most cancers animal mannequin with aggressive most cancers cells.

The corporate says that Telomir-1 actively suppresses most cancers progress and protects in opposition to chemotherapy-induced toxicity and mortality when mixed with Paclitaxel—a extensively used chemotherapy however typically related to extreme toxicity and negative effects.

Additionally Learn: Telomir Prescribed drugs Seeks To Faucet Multi-Billion-Greenback Market With Breakthrough In Silver Ion Stabilization For Antibacterial Therapy, Tissue Regeneration

Paclitaxel and different chemotherapy brokers induce toxicity largely by way of oxidative stress, which leads to extreme injury to wholesome cells and contributes to extreme negative effects.

The corporate says that Telomir-1 can reverse oxidative stress by way of its metallic ion-regulatory actions, which can be chargeable for eliminating chemotherapy-induced toxicity on this research.

“There has lengthy been a debate about whether or not telomere elongation might gas most cancers progress, however our findings present compelling proof that Telomir-1 does extra than simply lengthen telomeres—it actively suppresses tumor improvement…We’re seeing a drug that extends mobile well being whereas concurrently defending in opposition to the very toxicity that always limits therapy success,” mentioned Dr. Angel, Chief Scientific Advisor at Telomir.

Along with oncology, ongoing research are evaluating Telomir-1 in age-related ailments comparable to age-related macular degeneration (AMD) and Wilson’s illness, a uncommon orphan dysfunction affecting copper metabolism.

The corporate is prioritizing the quickest pathway to scientific trials and goals to submit its Investigational New Drug (IND) software by year-end.

In December, Telomir Prescribed drugs introduced preclinical findings highlighting the copper-binding potential of Telomir-1 as a possible therapy for Wilson’s illness and associated issues.

The compound displays a binding affinity for copper ions, enabling exact regulation of copper metabolism and interacting with important ions comparable to copper, iron, and zinc.

Worth Motion: TELO inventory closed at $4.12 on Tuesday.

Learn Subsequent: